Casdin Capital’s Foghorn Therapeutics FHTX Stock Holding History

Casdin Capital’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-215,000	Closed	-$3M	–	54
2021 Q3	$3M	Sell	215,000 -1,216	-0.6%	-$13.5K	0.07%	52
2021 Q2	$2.31M	Hold	216,216	–	–	0.06%	52
2021 Q1	$2.85M	Hold	216,216	–	–	0.08%	46
2020 Q4	$4.38M	Buy	+216,216	New	+$4.14M	0.13%	48

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Casdin Capital's FHTX Position: Q4 2021 in Review

Casdin Capital sold out of Foghorn Therapeutics (FHTX) in Q4 2021, closing a stake of 215,000 shares — an estimated $3M sold.

Casdin Capital first reported a position in FHTX in Q4 2020 and held it in 4 quarters. The position peaked at $4.38M in Q4 2020. 60 funds tracked by Wall St. Rank hold FHTX as of Q4 2021.

Casdin Capital reported no remaining Foghorn Therapeutics position as of Q4 2021 after selling out during the quarter.
Casdin Capital sold 215,000 Foghorn Therapeutics shares in Q4 2021, an estimated $3M.
Casdin Capital first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 4 quarters.
Casdin Capital's Foghorn Therapeutics position peaked at $4.38M in Q4 2020.
60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2021.

Based on Casdin Capital's 13F filing for Q4 2021, filed 14 Feb 2022.